Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 2/20 | 0.44 |
| ▸ | MMP13 | P45452 | 2/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2445674 | 0.89 | HRH4 (0.53) | ALDH1A1KDM4EHPGDHTTRECQL | |
| SCHEMBL29500514 | 0.84 | MAPT (0.44) | ALDH1A1KDM4EHPGDHTTRECQL | |
| SCHEMBL4314310 | 0.84 | MAPT (0.44) | ALDH1A1KDM4EHPGDHTTRECQL | |
| SCHEMBL16792659 | 0.83 | SIRT2 (0.50) | ALDH1A1KDM4EHPGDHTTRECQL | |
| SCHEMBL2445509 | 0.83 | GABRA1 (0.52) | ALDH1A1KDM4EHPGDHTTRECQL | |
| SCHEMBL3022374 | 0.81 | HRH4 (0.41) | ADORA3LMNASMN1; SMN2RAB9AMAPT | |
| SCHEMBL688815 | 0.80 | ALDH1A1 (0.53) | ALDH1A1KDM4EHPGDHTTRECQL | |
| SCHEMBL13373678 | 0.80 | KDM4E (0.49) | ALDH1A1KDM4EHPGDHTTRECQL | |
| SCHEMBL4296230 | 0.80 | HSD17B10 (0.61) | ALDH1A1KDM4EHPGDRECQLLMNA | |
| SCHEMBL26243739 | 0.79 | HRH4 (0.47) | ALDH1A1KDM4EHTTADORA3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718840-B2 | Condensed 5-oxazolidinone derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-08-01 | — | — | US | disclosed |
| US-9718840-B2 | Condensed 5-oxazolidinone derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-08-01 | — | — | US | disclosed |
| US-9718840-B2 | Condensed 5-oxazolidinone derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-08-01 | — | — | US | disclosed |
| US-20170022218-A1 | CONDENSED 5-OXAZOLIDINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-01-26 | — | — | US | disclosed |
| US-20170022218-A1 | CONDENSED 5-OXAZOLIDINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-01-26 | — | — | US | disclosed |
| US-20170022218-A1 | CONDENSED 5-OXAZOLIDINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-01-26 | — | — | US | disclosed |
| EP-3095786-A1 | CONDENSED 5-OXAZOLIDINONE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2016-11-23 | — | — | EP | disclosed |
| EP-3095786-A1 | CONDENSED 5-OXAZOLIDINONE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2016-11-23 | — | — | EP | disclosed |
| WO-2015107724-A1 | CONDENSED 5-OXAZOLIDINONE DERIVATIVE | 大日本住友製薬株式会社 | 2015-07-23 | — | — | WO | disclosed |
| EP-2046789-B1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS | INST NAT SANTE RECH MED (FR) | 2012-09-05 | — | — | EP | disclosed |
| EP-2363399-A1 | Labelled analogues of halobenzamides as radiopharmaceuticals | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2011-09-07 | — | — | EP | disclosed |
| EP-2363399-A1 | Labelled analogues of halobenzamides as radiopharmaceuticals | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2011-09-07 | — | — | EP | disclosed |
| US-20100061928-A1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2010-03-11 | — | — | US | disclosed |
| US-20100061928-A1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2010-03-11 | — | — | US | disclosed |
| EP-2046789-A2 | LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008012782-A2 | LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008012782-A2 | LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100061928-A1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS | HRH3, H1-3, HRH4 | ALDH1A1 794/4885KDM4E 3466/4885HPGD 2171/4885 |
| US-20170022218-A1 | CONDENSED 5-OXAZOLIDINONE DERIVATIVE | F2, SERPINC1, F12 | ALDH1A1 414/4885KDM4E 3853/4885HPGD 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.